

Press Release

Solactive and Evaluate Launch Solactive Evaluate Global Pharma Index, their first Co-Branded Index

July 27, 2023

FRANKFURT AM MAIN – With rapid advancements in medical research, technology, and increasing global demand for healthcare, the pharmaceutical industry is expected to experience substantial growth in the coming years. The COVID-19 pandemic has highlighted the crucial role of pharmaceutical companies in developing vaccines and therapeutics, driving investments and innovation in the sector. Additionally, the aging population and the prevalence of chronic diseases continue to drive the demand for innovative drugs and treatments. According to Evaluate Pharma, only prescription drug sales are forecast to grow at an annualized rate of 5.9% between 2023 and 2028, increasing from US\$ 1.1 trillion to US\$ 1.6 trillion. Envisaging this potential, Solactive leveraged its open architecture approach and partnered with Evaluate, a Norstella company, to launch the Solactive Evaluate Global Pharma Index.

The **Solactive Evaluate Global Pharma Index** represents securities with potential future revenues in the pharmaceutical industry. To be eligible for inclusion in the index, a company's total estimated future 5-year revenues must exceed US\$ 1 million and be derived from products and services in the following therapeutic areas: blood, cancer, cardiovascular, diabetes, gastrointestinal, hepatic & biliary, HIV & related conditions, hormone, immunology, infections, miscellaneous, musculoskeletal, neurology, psychiatry, oncology, reproduction, respiratory, sensory organs, skin, surgery, and urinary tract.

Timo Pfeiffer, Chief Markets Officer at Solactive, said: *"We are thrilled to partner with Evaluate to launch our first co-branded index with them, in a sector that plays a crucial role in advancing healthcare and addressing global challenges of our society. This collaboration highlights Solactive's open architecture approach and Evaluate's expertise in pharmaceutical insight, enabling us to leverage their knowledge and provide an index with a comprehensive representation of securities in the pharmaceutical industry. We look forward to continuing our partnership and developing more solutions together for the investment community."*

Kevin Morgan, Chief Data Operations Officer at Evaluate, commented: *"The importance of high-quality insight and forecasting in the pharmaceutical industry is critical for successful investments. By combining the capabilities and expertise of Evaluate and Solactive, this new index will enable the investment and trading community to benchmark key areas of growth, emerging pharmaceutical technologies, and clinical innovations that will enable them to make effective investment decisions."*

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Timo Pfeiffer
Chief Markets Officer
+49 (69) 719 160-320
timo.pfeiffer@solactive.com

Maria Seifert/Gabriela Ormazabal
PR & Communications
+49 (69) 719 160-311
press@solactive.com

For more information, please visit:

<http://www.solactive.com>

Note to editors

About Solactive

Solactive is a leading provider of indexing, benchmarking, and calculation solutions for the global investment and trading community. Headquartered in Frankfurt and, with offices in Hong Kong, Toronto, Berlin, Dresden, and Amsterdam, we innovate and disrupt the status quo as the partner of choice for our clients.

The unique blend of our 300 staff's expertise in data, data science, financial markets, and technology enables our clients' continued success through the delivery of a superior experience, unique customization capabilities, and the best value for money available in the industry. With more than 26,000 indices calculated daily, we offer a full suite of solutions, including market-leading ESG and thematic indices.

As at January 2023, Solactive served approximately 500 clients across the world, with approximately US\$300 billion invested in products linked to our indices. Solactive is registered with ESMA as a benchmark administrator and is supervised by the BaFin.

Disclaimer

The information in this document does not constitute tax, legal or investment advice and is not intended as a recommendation for buying or selling securities. Solactive AG and all other companies mentioned in this document are not responsible for the consequences of reliance upon any opinion or statement contained herein or for any omission.

Solactive AG, Platz der Einheit 1, 60327 Frankfurt am Main, Germany. Registered Office: Frankfurt am Main, Registration Court: Amtsgericht Frankfurt am Main, HRB: 79986, USt-IdNr.: DE 255 598 976. Management Board: Steffen Scheuble, Alexander Steiner, and Timo Pfeiffer, Head of Supervisory Board: Dr Felix Mühlhäuser.

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Timo Pfeiffer
Chief Markets Officer
+49 (69) 719 160-320
timo.pfeiffer@solactive.com

Maria Seifert/Gabriela Ormazabal
PR & Communications
+49 (69) 719 160-311
press@solactive.com